Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q37335700)
Watch
English
Deprenyl: protective vs. symptomatic effect
scientific article published on February 1991
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed ID
1903668
retrieved
19 August 2017
review article
1 reference
stated in
Europe PubMed Central
title
Deprenyl: protective vs. symptomatic effect
(English)
1 reference
stated in
Europe PubMed Central
PubMed ID
1903668
retrieved
19 August 2017
author name string
Kofman OS
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
1903668
retrieved
19 August 2017
publication date
1 February 1991
1 reference
stated in
Europe PubMed Central
PubMed ID
1903668
retrieved
19 August 2017
published in
Canadian Journal of Neurological Sciences
1 reference
stated in
Europe PubMed Central
PubMed ID
1903668
retrieved
19 August 2017
volume
18
1 reference
stated in
Europe PubMed Central
PubMed ID
1903668
retrieved
19 August 2017
issue
1
1 reference
stated in
Europe PubMed Central
PubMed ID
1903668
retrieved
19 August 2017
page(s)
83-85
1 reference
stated in
Europe PubMed Central
PubMed ID
1903668
retrieved
19 August 2017
cites work
Evidence to support early levodopa therapy in Parkinson disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1017%2FS0317167100031358
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Deprenyl as prophylaxis against Parkinson's disease?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1017%2FS0317167100031358
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical neuromythology IX. Pyramid sale in the bucket shop: DATATOP bottoms out
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1017%2FS0317167100031358
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of deprenyl on the progression of disability in early Parkinson's disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1017%2FS0317167100031358
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Selegiline as primary treatment in early phase Parkinson's disease--an interim report
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1017%2FS0317167100031358
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1017%2FS0317167100031358
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1017%2FS0317167100031358
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenil
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1017%2FS0317167100031358
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Deprenyl in Parkinson's disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1017%2FS0317167100031358
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Selegiline use to prevent progression of Parkinson's disease. Experience in 22 de novo patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1017%2FS0317167100031358
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1017%2FS0317167100031358
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1017%2FS0317167100031358
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1017/S0317167100031358
0 references
PubMed ID
1903668
1 reference
stated in
Europe PubMed Central
PubMed ID
1903668
retrieved
19 August 2017
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
